2024-Low dose Interleukin 2 Therapy Fine tuning Treg in Solid Organ Transplantation > 1분 논문읽기

본문 바로가기


연구소 자료

KOSIN UNIVERSITY COLLEGE OF MEDICINE

2024-Low dose Interleukin 2 Therapy Fine tuning Treg in Solid Organ Tr…

페이지 정보

작성자 신호식 작성일24-07-28 16:10 조회163회 댓글0건

첨부파일

본문

2024-Low dose Interleukin 2 Therapy Fine tuning Treg in Solid Organ Transplantation

Regulatory T cells (Treg), a subset of CD4+ T cells, are potent regulators of immune reactions, which have been
shown to be a promising therapeutic alternative to toxic immunosuppressive drugs. Data support the utility of Treg in managing
immunopathologies, including solid organ transplant rejection, graft-versus-host disease, and autoimmune disorders.
Notably, reports suggest that interleukin-2 (IL-2) is critical to survival of Treg, which constitutively express high levels of CD25,
that is, the IL-2 receptor α-chain, and are exquisitely sensitive to IL-2, even at very low concentrations in contrast to effector
T cells, which only upregulate IL-2 receptor α-chain on activation. This has led to the notion of using low doses of exogenous
IL-2 therapeutically to modulate the immune system, specifically Treg numbers and function. Here, we summarize developments
of clinical experience with low-dose IL-2 (LD-IL-2) as a therapeutic agent. So far, no clinical data are available to support
the therapeutic use of LD-IL-2 therapy in the solid organ transplant setting. For the latter, fine-tuning by biotechnological
approaches may be needed because of the narrow therapeutic window and off-target effects of LD-IL-2 therapy and so to
realize the therapeutic potential of this molecule.
(Transplantation 2024;108: 1492–1508).



(49267) 부산광역시 서구 감천로(장기려로) 262 고신대학교 의과대학 / 사무팀 Tel. 051-990-6406 Fax. 051-241-5458 / 교학관리팀 Tel. 051-990-6600 Fax. 051-241-0145
Copyright © www.kucm.ac.kr All rights reserved.
^